Information Provided By: 
Fly News Breaks for June 10, 2015
BLUE
Jun 10, 2015 | 09:02 EDT
After bluebird bio announced that the National Institutes of Health Recombinant DNA Advisory Committee recommended bluebird delay initiation of its pediatric LentiGlobin study in the United States for one to two years, Wedbush says that the committee's recommendation is non-binding and will not affect the FDA. The firm expects data slated to be released this weekend on an SCD patient being treated with Lentiglobin to show that the patient's condition has improved further. The firm recommends buying the stock ahead of the data.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
